6a edición clínica. Nuevo: 4. Vacunas (26 de abril); Nuevo: 5. Pruebas y procedimientos de diagnóstico (7 de abril); Nuevo: 7. COVID-19 persistente (7 de abril)

Il nuovo mini-textbook Nei prossimi mesi, COVID Reference presenterà aggiornamenti regolari e racconterà i dati scientifici nel modo più completo possibile.

15 July 2021. This report describes the demographics, clinical presentation, clinical outcomes, and risk factors among people living with HIV (PLHIV) who have been hospitalized for suspected or confirmed COVID-19. The specific objectives of the analysis were to: describe the clinical characteristics and outcomes of PLHIV hospitalized for COVID-19 assess whether PLHIV hospitalized with COVID-19 were at increased risk of presenting with severe or critical illness at admission and were at increased risk of in-hospital death compared to individuals not infected with HIV assess risk factors associated with severe or critical illness at hospital admission and of in-hospital death among PLHIV hospitalized for COVID-19

Practical Approach to Care Kit Kit de Cuidados em Atenção Primária Guia de manejo clínico da COVID 19 para Atenção Primária O PACK Brasil é uma parceria entre a Unidade de Tradução do Conhecimento (KTU), Secretaria Municipal de Saúde de Florianópolis/SC, BMJ e Fundação ProAR. A Fundação ProAR é a líder oficial das atividades do PACK no Brasil. Mais informações sobre a ProAR podem ser encontradas em: www.fundacaoproar.org.br O PACK foi adaptado, traduzido, implementado e avaliado em serviços de atenção primária brasileiros entre 2015 e 2017. Um ensaio clínico randomizado concluiu que o PACK qualificou o atendimento clínico de pacientes adultos com doenças respiratórias crônicas na atenção primária e apoiou o compartilhamento do cuidado entre médicos e enfermeiros. Desde então, foi revisado anualmente, estando alinhado com as políticas públicas locais. Em 2021, foi desenvolvido conteúdos adicionais sobre o manejo da COVID-19

Practical Approach to Care Kit Kit de Cuidados em Atenção Primária Guia de manejo clínico da COVID 19 para Atenção Primária O PACK Brasil é uma parceria entre a Unidade de Tradução do Conhecimento (KTU), Secretaria Municipal de Saúde de Florianópolis/SC, BMJ e Fundação ProAR. A Fundação ProAR é a líder oficial das atividades do PACK no Brasil. Mais informações sobre a ProAR podem ser encontradas em: www.fundacaoproar.org.br O PACK foi adaptado, traduzido, implementado e avaliado em serviços de atenção primária brasileiros entre 2015 e 2017. Um ensaio clínico randomizado concluiu que o PACK qualificou o atendimento clínico de pacientes adultos com doenças respiratórias crônicas na atenção primária e apoiou o compartilhamento do cuidado entre médicos e enfermeiros. Desde então, foi revisado anualmente, estando alinhado com as políticas públicas locais. Em 2021, foi desenvolvido conteúdos adicionais sobre o manejo da COVID-19

Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to identify areas that need further attention to enable the facility to respond effectively to the pandemic. The tool encompasses key components that are essential to managing COVID-19 in a hospital setting, including: health workforce (numbers, absences, COVID-19 infections, staff vaccinated for COVID-19 health workforce management, training and support); medicines and medical supplies for management of COVID-19; IPC capacities (protocols, safety measures, guidelines) and the availability of personal protective equipment (PPE) for staff; diagnostic testing, imaging and patient monitoring devices and supplies medical equipment for management of COVID-19, including O2 administration; COVID-19 vaccine readiness ; beds and space capacity

6 July 2021 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges. This fifth version of the WHO guideline now contains seven recommendations, including a new recommendation regarding interleukin-6 (IL-6) receptor blockers, including both tocilizumab and sarilumab. This latest update was initiated in response to publication of the RECOVERY and REMAP-CAP trials addressing IL-6 receptor blockers as a potential treatment for COVID-19. No further updates to the previous existing recommendations were made in this latest version. This recommendation, which applies to patients with COVID-19 of any disease severity, is now part of WHO’s guidelines on COVID-19 treatments. Ivermectin is a broad spectrum anti-parasitic agent, included in WHO essential medicines list for several parasitic diseases. It is used in the treatment of onchocerciasis (river blindness), strongyloidiasis and other diseases caused by soil transmitted helminthiasis. It is also used to treat scabies

Community health workers (CHWs) serve as a very important direct link between patients, communities and health services. As trusted on-the-ground support to community members, they therefore expand access to essential healthcare information as well as available treatment and prevention programmes. This course book provides appropriate, cost-effective, and sustainable targeted learning for the large numbers of emerging community health workers in South Africa

This module is updated as new research and best practice becomes available. We recommend checking back regularly. Major changes will be listed